Drug Search Results
More Filters [+]

Buclizine

Alternative Names: buclizine, bucladin-s
Latest Update: 2025-01-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Brazil | Colombia | Ecuador | India | Ireland | Israel | Italy | Malta | Morocco | Peru | Philippines | Portugal | Saudi Arabia | Singapore | Spain | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Moderna Therapeutics Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Buclizine

Countries in Clinic: Poland

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PTG007DM1preTREG001

P2

Unknown Status

Type 1 Diabetes

2032-10-31

Recent News Events

Date

Type

Title